Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellaVision ABCHIX:CEVIS 95 EV-to-EBIT is 19.25 as of Jul. 18, 2026, which is 51% below its 10-year median of 39.15. GuruFocus rates CHIX:CEVIS with a GF Score™ of 95/100 and a GF Value™ of kr229.72. The stock has 1 warning sign investors should review. Among 466 Medical Devices & Instruments companies, CellaVision AB ranks better than 54.29% on this metric.
The historical rank and industry rank for CellaVision AB's EV-to-EBIT or its related term are showing as below:
CHIX:CEVIs'
s EV-to-EBIT Range Over the Past 10 Years
Min: 14.85 Med: 39.15 Max: 89.58
Current: 19.25
During the past 13 years, the highest EV-to-EBIT of CellaVision AB was 89.58. The lowest was 14.85. And the median was 39.15.
CHIX:CEVIs's EV-to-EBIT is ranked better than 54.29% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 18.46
vs CHIX:CEVIs: 19.25
CellaVision AB (CHIX:CEVIs) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
CellaVision AB's Enterprise Value for the quarter that ended in Mar. 2026 was kr3,613.3 Mil.
CellaVision AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr176.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellaVision AB EV-to-EBIT Related Terms
CellaVision AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for CellaVision AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CEVIS vs ABT, SYK, MDT: EV-to-EBIT Comparison
For the Medical Devices subindustry, CellaVision AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where CellaVision AB's EV-to-EBIT falls into.
CellaVision AB's current Enterprise Value is kr3,391.0 Mil.
CellaVision AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr176.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellaVision AB (CHIX:CEVIS) has a EV-to-EBIT of 19.25 as of Jul. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CellaVision AB and its competitors. This is 51% below median its historical median of 39.15. Over the past decade, CellaVision AB's EV-to-EBIT has ranged from 14.85 to 89.58. According to the industry distribution chart, CellaVision AB ranks #213 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 45.7%.
Is CellaVision AB's EV-to-EBIT too high?
CellaVision AB's current EV-to-EBIT of 19.25 is 51% below median its 10-year median of 39.15. Over the past 10 years, this metric has ranged from a low of 14.85 to a high of 89.58. The Medical Devices & Instruments industry median EV-to-EBIT is 18.46. CellaVision AB's value of 19.25 is 4.3% above this industry median. Based on the distribution chart, CellaVision AB ranks #213 out of 466 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, CellaVision AB has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #213 out of 466 companies for EV-to-EBIT. This puts CellaVision AB in the upper half of its industry. The industry median EV-to-EBIT is 18.46. CellaVision AB's value of 19.25 is 4.3% above this benchmark. Historically, CellaVision AB's own EV-to-EBIT has ranged from 14.85 to 89.58 over the past decade. While the company's 10-year median is 39.15 vs. the industry median of 18.46, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.46, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current EV-to-EBIT of 19.25 is 4.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current EV-to-EBIT is 19.25, which is 51% below median its own 10-year median of 39.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
CellaVision AB (CHIX:CEVIS) has a current EV-to-EBIT of 19.25. The stock's GF Value™ is kr229.72, compared to a current price of kr160.20 — trading 30.3% below its estimated fair value. The current EV-to-EBIT is 19.25, which is 51% below median its 10-year median of 39.15 and 4.3% above the Medical Devices & Instruments industry median of 18.46. CellaVision AB's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For CellaVision AB (CHIX:CEVIS), the current EV-to-EBIT is 19.25 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CHIX:CEVIS) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of kr160.20 is trading 30.3% below its estimated GF Value™ of kr229.72.
Key valuation signals for CHIX:CEVIS:
EV-to-EBIT: 19.25 (51% below median its 10-year median of 39.15)
GF Value™: kr229.72 vs. price of kr160.20 (30.3% below fair value)
Industry Position: 4.3% above the Medical Devices & Instruments median (#213 of 466)
No single metric tells the full story. See the CHIX:CEVIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
95GF Score
Get the complete analysis for CHIX:CEVIS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CEVIS has been successfully added to your 
